Why the study?
Epithelioid hemangioma and epithelioid hemangioendothelioma are rare vascular tumors with distinct treatment challenges and a lack of established guidelines.
Does pazopanib and surgical resection improve symptoms and stabilize tumors in patients with rare vascular tumors?
Does pazopanib and surgical resection improve symptoms and stabilize tumors in patients with rare vascular tumors?
Pazopanib and minimally invasive surgical resection may serve as effective salvage therapies for rare vascular tumors such as epithelioid hemangioma and epithelioid hemangioendothelioma.
Case reports suggest pazopanib for EH/EHE; hypothesis-generating and leaves open need for prospective trials.
Epithelioid hemangioma (EH) and epithelioid hemangioendothelioma (EHE) are both rare vascular tumors. EH tumors are often benign while EHE tumors have moderate malignant potential. Here, we present three unique cases at Soroka Medical Center, two featuring EH of the bone and one presenting EHE of the mediastinum. Each case demonstrates distinct treatment challenges due to the rarity of both diseases and lack of established guidelines. We propose three treatment approaches including pazopanib for salvage therapy of EH of the bone and minimally invasive surgical resection which in these cases lead to complete symptom relief and tumor stabilization upheld over time with close follow-up.
No takes yet. Share an insight, caveat, or question.
Yakobson et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: